Comparison Overview

Johnson & Johnson Innovative Medicine

VS

Astellas Pharma

Johnson & Johnson Innovative Medicine

None
Last Update: 2026-01-18

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 37,729
Subsidiaries: 10
12-month incidents
0
Known data breaches
0
Attack type number
0

Astellas Pharma

2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo, JP, 103-8411
Last Update: 2026-01-18
Between 750 and 799

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,110
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/astellaspharmainc.jpeg
Astellas Pharma
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Johnson & Johnson Innovative Medicine
100%
Compliance Rate
0/4 Standards Verified
Astellas Pharma
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Johnson & Johnson Innovative Medicine in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Astellas Pharma in 2026.

Incident History — Johnson & Johnson Innovative Medicine (X = Date, Y = Severity)

Johnson & Johnson Innovative Medicine cyber incidents detection timeline including parent company and subsidiaries

Incident History — Astellas Pharma (X = Date, Y = Severity)

Astellas Pharma cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
Incidents

No Incident

https://images.rankiteo.com/companyimages/astellaspharmainc.jpeg
Astellas Pharma
Incidents

No Incident

FAQ

Both Johnson & Johnson Innovative Medicine company and Astellas Pharma company demonstrate a comparable AI Cybersecurity Score, with strong governance and monitoring frameworks in place.

Historically, Astellas Pharma company has disclosed a higher number of cyber incidents compared to Johnson & Johnson Innovative Medicine company.

In the current year, Astellas Pharma company and Johnson & Johnson Innovative Medicine company have not reported any cyber incidents.

Neither Astellas Pharma company nor Johnson & Johnson Innovative Medicine company has reported experiencing a ransomware attack publicly.

Neither Astellas Pharma company nor Johnson & Johnson Innovative Medicine company has reported experiencing a data breach publicly.

Neither Astellas Pharma company nor Johnson & Johnson Innovative Medicine company has reported experiencing targeted cyberattacks publicly.

Neither Johnson & Johnson Innovative Medicine company nor Astellas Pharma company has reported experiencing or disclosing vulnerabilities publicly.

Neither Johnson & Johnson Innovative Medicine nor Astellas Pharma holds any compliance certifications.

Neither company holds any compliance certifications.

Johnson & Johnson Innovative Medicine company has more subsidiaries worldwide compared to Astellas Pharma company.

Johnson & Johnson Innovative Medicine company employs more people globally than Astellas Pharma company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Johnson & Johnson Innovative Medicine nor Astellas Pharma holds SOC 2 Type 1 certification.

Neither Johnson & Johnson Innovative Medicine nor Astellas Pharma holds SOC 2 Type 2 certification.

Neither Johnson & Johnson Innovative Medicine nor Astellas Pharma holds ISO 27001 certification.

Neither Johnson & Johnson Innovative Medicine nor Astellas Pharma holds PCI DSS certification.

Neither Johnson & Johnson Innovative Medicine nor Astellas Pharma holds HIPAA certification.

Neither Johnson & Johnson Innovative Medicine nor Astellas Pharma holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Improper validation of specified type of input in M365 Copilot allows an unauthorized attacker to disclose information over a network.

Risk Information
cvss3
Base: 9.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:N
Description

Improper access control in Azure Front Door (AFD) allows an unauthorized attacker to elevate privileges over a network.

Risk Information
cvss3
Base: 9.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
Description

Azure Entra ID Elevation of Privilege Vulnerability

Risk Information
cvss3
Base: 9.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:L/A:N
Description

Moonraker is a Python web server providing API access to Klipper 3D printing firmware. In versions 0.9.3 and below, instances configured with the "ldap" component enabled are vulnerable to LDAP search filter injection techniques via the login endpoint. The 401 error response message can be used to determine whether or not a search was successful, allowing for brute force methods to discover LDAP entries on the server such as user IDs and user attributes. This issue has been fixed in version 0.10.0.

Risk Information
cvss4
Base: 2.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:U/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Runtipi is a Docker-based, personal homeserver orchestrator that facilitates multiple services on a single server. Versions 3.7.0 and above allow an authenticated user to execute arbitrary system commands on the host server by injecting shell metacharacters into backup filenames. The BackupManager fails to sanitize the filenames of uploaded backups. The system persists user-uploaded files directly to the host filesystem using the raw originalname provided in the request. This allows an attacker to stage a file containing shell metacharacters (e.g., $(id).tar.gz) at a predictable path, which is later referenced during the restore process. The successful storage of the file is what allows the subsequent restore command to reference and execute it. This issue has been fixed in version 4.7.0.

Risk Information
cvss3
Base: 8.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:H/A:H